The Role of Complement Pathway Inhibitors in the Management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Will We See a New Paradigm for SPAF? Which Patients Are More Likely to Benefit from FXIa Inhibition vs DOACs?
Advanced Curriculum for Multiple Sclerosis
New Approaches to Managing Dyslipidemia: Primary Prevention with a PCSK9 Inhibitor
